Welcome to our dedicated page for Petvivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biomedical company’s disclosures is challenging—especially when Petvivo Holdings transforms complex human biomaterials into Spryng™ injections for pets. Revenue drivers hide in patent tables, while details about clinical milestones and distribution deals are scattered across multiple forms. If you have struggled to locate Petvivo Holdings insider trading Form 4 transactions or to decode a 300-page prospectus, you are not alone.
Stock Titan’s AI breaks down every document the moment it reaches EDGAR. Our platform delivers concise summaries, highlights crucial numbers, and links each insight back to the original page, so understanding Petvivo Holdings SEC documents with AI becomes straightforward. Whether you need a Petvivo Holdings quarterly earnings report 10-Q filing, an 8-K material events explained alert, or a proxy statement executive compensation table, you will find it here—complete with real-time updates and side-by-side comparisons.
Use the data to:
- Track Petvivo Holdings executive stock transactions Form 4 before product announcements.
- Compare segment revenue trends with our earnings report filing analysis.
- Review patent disclosures inside the annual report 10-K simplified.
From Petvivo Holdings Form 4 insider transactions real-time alerts to plain-language notes on R&D spending, our AI-powered summaries eliminate guesswork. Make faster, better-informed decisions—no more searching line-by-line through dense biomedical language.
PetVivo Holdings, Inc. reporting person John Lai, who serves as Chief Executive Officer and a director, reported a non‑derivative acquisition on 09/18/2025. The filing shows a grant of 84,375 shares of common stock at a price of $0.76 to a corporation owned by the reporting person as compensation for past performance, reflecting conversion of a past accrued bonus into common stock. Following the transaction, the reporting person (indirectly) beneficially owned 2,020,710 shares. The Form 4 is signed by John Lai on 09/22/2025. The filing indicates the award was issued as compensation rather than a market purchase.
Garry Lowenthal, Chief Financial Officer of PetVivo Holdings, Inc., received a grant of restricted common stock on 09/18/2025 as compensation for past performance. The grant consisted of 79,375 shares at a stated price of $0.76 and was issued to a corporation owned by Mr. Lowenthal. After the reported transaction, the reporting persons indirect beneficial ownership totaled 592,967 shares. The Form 4 indicates this was a non-derivative award recorded as an acquisition and identifies the grant as compensation rather than a market purchase.
FAQ
What is the current stock price of Petvivo Holdings (PETVW)?
